Navigation Links
Pharmacyclics Announces It Received Nasdaq Notice of Compliance
Date:5/30/2008

SUNNYVALE, Calif., May 30 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has received notice from The Nasdaq Stock Market that the company has regained compliance with Marketplace Rule 4450(a)(5) (the "Rule") relating to the maintenance of a minimum $1.00 bid price of the Company's common stock. Nasdaq had previously notified the company on April 17, 2008 that its common stock had failed to maintain a minimum bid price of at least $1.00 per share over the previous 30 consecutive business days as required by the Rule, and that the Company had 180 calendar days to regain compliance. Since then, the closing bid price of the company's common stock has been at $1.00 per share or greater for at least 10 consecutive business days. Accordingly, Nasdaq has determined that the Company has regained compliance with the Rule.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmacyclics Announces It Received Nasdaq Notification
2. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
3. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
4. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
5. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
6. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
7. Favrille Announces Workforce Reduction
8. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
9. Genmab Announces 2008 First Quarter Results
10. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
11. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... internist, who will review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. ... 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with ...
(Date:4/27/2017)... , April 27, 2017  Pendant Biosciences, Inc. ... innovative surface modification and drug delivery technologies, today announced ... Innovation, JLABS @ Toronto . ... Officer of Pendant Biosciences, noted, "We are excited to ... community, and are honored to be the ...
(Date:4/26/2017)... Centennial, CO (PRWEB) , ... April 25, 2017 , ... ... test offerings were added to its extensive test menu: Nucleic Acid Testing (NAT) ... that time, LABS was only able to offer NAT screening for blood donors under ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):